Interestingly, it has been recently reported that small molecule inhibitors of NRF2 pathway sensitize cancer cells carrying KEAP1 mutants to chemotherapy59 and that inhibition of SKP2 sensitizes lung cancer cells to paclitaxel60,61. The gene discussed is NFE2L2; the disease is lung carcinoma.